Investor Relations

Company Overview

Qualigen Therapeutics is a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation. Our investigational QN-302 compound is a small molecule selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells; such binding could, by stabilizing the G4s against “unwinding,” help inhibit cancer cell proliferation. The investigational compounds within Qualigen’s family of Pan-RAS oncogene protein-protein interaction inhibitor small molecules are believed to inhibit or block the binding of mutated RAS genes’ proteins to their effector proteins, thereby leaving the proteins from the mutated RAS unable to cause further harm. In theory, such mechanism of action may be effective in the treatment of about one quarter of all cancers, including certain forms of pancreatic, colorectal, and lung cancers. Our investigational QN-247 compound inhibits nucleolin, a key multi-functional regulatory protein that is overexpressed in cancer cells; QN-247 may thereby be able to inhibit the cells’ proliferation. QN-247 has shown promise in preclinical studies for the treatment of acute myeloid leukemia (AML).

In July 2023, Qualigen sold its FastPack® diagnostics business to Chembio Diagnostics, Inc., an American subsidiary of French diagnostics provider BIOSYNEX Group, a leader in the design and distribution of rapid tests.

Stock Snapshot

Nasdaq: QLGN

Qualigen Therapeutics, Inc.

Latest Presentation

Industry Classifications

Sector:

Healthcare

SIC:

Pharmaceutical Preparations (2834)

NAICS:

Pharmaceutical Preparation Manufacturing (325412)

Industry:

Biotechnology

Latest News

FAQ

Our stock is traded on the Nasdaq under the symbol QLGN.

Ritter Pharmaceuticals, Inc. (our predecessor) was formed as a Nevada limited liability company on March 29, 2004 under the name Ritter Natural Sciences, LLC. In September 2008, this company converted into a Delaware corporation under the name Ritter Pharmaceuticals, Inc. On May 22, 2020, upon completing a “reverse recapitalization” transaction with Qualigen, Inc., Ritter Pharmaceuticals, Inc. was renamed Qualigen Therapeutics, Inc. Qualisys Diagnostics, Inc. was formed as a Minnesota corporation in 1996, reincorporated to become a Delaware corporation in 1999, and then changed its name to Qualigen, Inc. in 2000. Qualigen, Inc. was a wholly-owned subsidiary of the Company. On July 20, 2023, we sold all of the issued and outstanding shares of common stock of Qualigen, Inc. to Chembio Diagnostics, Inc. (“Chembio”), a wholly-owned subsidiary of Biosynex, S.A. Following the consummation of this transaction, Qualigen, Inc. became a wholly-owned subsidiary of Chembio. 

June 29, 2015 as Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR). Renamed Qualigen Therapeutics, Inc. on May 22, 2020 (Nasdaq: QLGN).

5857 Owens Avenue
Suite 300
Carlsbad, CA 92008

EQ Shareowner Services
PO Box 64874
St Paul MN 55164
T: 800-468-9716
ShareownerOnline.com

Sign Up For IR Email Alerts

Receive updates straight into your inbox

Investor Contact Information

Company

Qualigen Therapeutics, Inc.
5857 Owens Ave
Suite 300
Carlsbad, CA 92008
T: +760-452-8111
ir@qualigentx.com

Investor Relations

Transfer Agent

EQ Shareowner Services
PO Box 64874
St Paul, MN 55164
T: +8004689716
ShareownerOnline.com